Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Portfolio Pulse from
Phio Pharmaceuticals Corp. is set to present new clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The company focuses on using its INTASYL® siRNA gene silencing technology to enhance immune cell effectiveness against cancer.
November 07, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phio Pharmaceuticals will present new clinical data at the SITC meeting, potentially boosting investor confidence in its INTASYL® siRNA technology for cancer treatment.
The presentation of new clinical data at a major conference like SITC can increase visibility and credibility for Phio Pharmaceuticals, potentially leading to positive investor sentiment and a short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100